Gilead Says 11% of Prior Non-Responders Cured in Hepatitis Trial

Gilead Sciences Inc.’s experimental hepatitis C drug cleared the virus in 11 percent of patients who hadn’t responded to prior treatment, the company said today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.